Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDCA stimulation study of the bile salt-FXR-FGF19 axis in quiescent Crohn's colitis
NL-OMON33880Withdrawn
- Sponsor
- University Medical Center Utrecht
- Start
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of chenodeoxycholic acid in Crohn's disease, Crohn's colitis and inflammatory bowel disease (IBD) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Difference in bile salt-stimulated fasting gallbladder volume increase, Difference in bile salt-stimulated fasting FGF19 increase and 1 more. Planned start Mar 2009; status: withdrawn.
02
Drugs
chenodeoxycholic acid
03
Conditions
Crohn's diseaseCrohn's colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON33880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33880.